Long-term protection of hepatitis B vaccine 18 years after vaccination

92Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Introduction: This is the third evaluation study of the hepatitis B virus (HBV) vaccination program, initiated in 1989 in Saudi Arabia. Aims: This study sought to assess the efficacy and long-term protection of the hepatitis B vaccine among Saudi adolescents. Methods: School students between the ages of 16 and 18 years were randomly chosen from high endemic (Aseer), intermediate endemic (Madinah), and low endemic (Al-Qaseem) areas of the country. Hepatitis B surface antigen (HBsAg), hepatitis B core IgG antibody (anti-HBc), and hepatitis B surface antibody (anti-HBs) were measured using standard techniques. Results: A total of 1355 students (689 males and 666 females) were selected randomly from the three areas. No cases of positive HBsAg or anti-HBc were detected among the study population. Five hundred and ten students (38%) showed protective anti-HBs titers (≥10 mIU/ml), while 528 (39%) students had undetectable anti-HBs titers (<1 mIU/ml). Conclusions: This study shows the excellent efficacy of the HBV vaccination program in Saudi Arabia 18 years after its launch. Based on this study and others, a booster dose for the adult population appears to be unnecessary. © 2008 The British Infection Society.

Cite

CITATION STYLE

APA

AlFaleh, F., AlShehri, S., AlAnsari, S., AlJeffri, M., AlMazrou, Y., Shaffi, A., & Abdo, A. A. (2008). Long-term protection of hepatitis B vaccine 18 years after vaccination. Journal of Infection, 57(5), 404–409. https://doi.org/10.1016/j.jinf.2008.08.008

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free